Recognised as innovation leaders, and experts in the field of drowsiness detection, Optalert has developed a revolutionary objective measurement of eye and eyelid movement, called Blepharometry. This is the next generation of drowsiness/wakefulness measurements for use in clinical drug trials.
The Optalert MediQ Solution uses Blepharometry and patented algorithms to accurately quantify drowsiness or wakefulness, against the validated Johns Drowsiness Scale (JDS) (clicking, will link to content below). This future-proofed approach to clinical development, can advance clinical drug trial timelines and deliver new therapies to market faster.
Current methodologies for measuring drowsiness or wakefulness are used across a wide range of clinical drug trials including opioids, anti-depressants, shift worker disorder and insomnia medications. Optalert’s MediQ Solution is the next generation methodology for pharmaceutical drug trials which:
- Detects and quantifies alertness, wakefulness and drowsiness
- Monitors and measures adverse effects of medication
- Provides simultaneous computerised vigilance testing and Infrared oculography (IRO) recording capabilities
Optalert is now transforming the way pharmaceutical companies are able to verify the efficacy and safety of drugs in clinical trials.